SKI Market

A+| A| A-| Skip to Main Content

Indian Indices

Sensex

71,970.49 -668.21
( -0.92%)

Global Indices

Nasdaq

51,194.40 -347.88
(-0.67%)

Dow Jones

7,822.15 -17.78
(-0.23%)

Hang Seng

70,229.08 -454.90
(-0.64%)

Nikkei 225

10,456.95 -84.74
(-0.80%)

Forex

USD-INR

96.37 0.10
(0.10%)

EUR-INR

108.33 0.45
(0.42%)

GBP-INR

127.68 0.44
(0.34%)

JPY-INR

0.61 0.00
(0.01%)

YOU ARE HERE :
HOME
Markets
Equity
Company News Details

EQUITY - MARKET SCREENER

Marksans Pharma Ltd

Industry : Pharmaceuticals - Indian - Formulations

BSE Code

ISIN Demat

Book Value()

524404

INE750C01026

36.4616629

NSE Symbol

P/E(TTM)

Mar.Cap( Cr.)

MARKSANS

45.82

14741.42

EPS(TTM)

Face Value()

Div & Yield %

7.1

0.28

Back

NCL Research and Financial Services standalone net profit declines 33.53% in the June 2026 quarter

Aug 11,2026

Net profit of NCL Research and Financial Services declined 33.53% to Rs 1.13 crore in the quarter ended June 2026 as against Rs 1.70 crore during the previous quarter ended June 2025. Sales declined 8.24% to Rs 1.67 crore in the quarter ended June 2026 as against Rs 1.82 crore during the previous quarter ended June 2025.

Particulars	Quarter Ended
	Jun. 2026	Jun. 2025	% Var.
Sales	1.67	1.82	-8
OPM %	56.89	82.42	-
PBDT	1.50	2.28	-34
PBT	1.49	2.27	-34
NP	1.13	1.70	-34

71,970.49 -668.21 ( -0.92%)

51,194.40 -347.88 (-0.67%)

7,822.15 -17.78 (-0.23%)

70,229.08 -454.90 (-0.64%)

10,456.95 -84.74 (-0.80%)

96.37 0.10 (0.10%)

108.33 0.45 (0.42%)

127.68 0.44 (0.34%)

0.61 0.00 (0.01%)